CLINICAL TRIALS PROFILE FOR TOBRAMYCIN

All Clinical Trials for Tobramycin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004829 ↗	Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis	Completed	FDA Office of Orphan Products Development	Phase 3	1995-06-01	OBJECTIVES: I. Determine the safety and efficacy of tobramycin in patients with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa. II. Determine whether this treatment produces tobramycin-resistant bacteria at a frequency different from the placebo group and whether the emergence of resistance is associated with a lack of clinical response.
NCT00006280 ↗	A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis	Completed	National Center for Research Resources (NCRR)	Phase 2	2000-02-01	This study's primary goals are to test the safety and effectiveness of Tobramycin for Inhalation (TOBIr) in cystic fibrosis (CF) patients who are between 6 months and 6 years of age. This drug is an antibiotic that is inhaled into the lungs by the patient. It has already been studied and approved by the FDA for treatment of CF patients 6 years and older. Lung fluid will be examined for bacteria before and after the 28-day treatment. The amount of bacteria before and after treatment will be compared. This will indicate whether the antibiotic was effective in killing bacteria in the lungs. Once treatment begins, patients will be monitored every 2 weeks throughout the study (5 exams in 56 days). Half of the patients will receive TOBIr, half will receive a placebo (a substance that looks like TOBIr but contains no medication).
NCT00006280 ↗	A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2	2000-02-01	This study's primary goals are to test the safety and effectiveness of Tobramycin for Inhalation (TOBIr) in cystic fibrosis (CF) patients who are between 6 months and 6 years of age. This drug is an antibiotic that is inhaled into the lungs by the patient. It has already been studied and approved by the FDA for treatment of CF patients 6 years and older. Lung fluid will be examined for bacteria before and after the 28-day treatment. The amount of bacteria before and after treatment will be compared. This will indicate whether the antibiotic was effective in killing bacteria in the lungs. Once treatment begins, patients will be monitored every 2 weeks throughout the study (5 exams in 56 days). Half of the patients will receive TOBIr, half will receive a placebo (a substance that looks like TOBIr but contains no medication).
NCT00097773 ↗	Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis	Completed	CF Therapeutics Development Network Coordinating Center	Phase 2	2004-09-01	Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main causes of death in individuals with CF. The purpose of this study is to compare the effectiveness of treatment based on quarterly culture results versus consistent quarterly antibiotic treatment at reducing PA infection in children with CF.
NCT00097773 ↗	Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis	Completed	Cystic Fibrosis Foundation	Phase 2	2004-09-01	Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main causes of death in individuals with CF. The purpose of this study is to compare the effectiveness of treatment based on quarterly culture results versus consistent quarterly antibiotic treatment at reducing PA infection in children with CF.
NCT00097773 ↗	Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis	Completed	Cystic Fibrosis Foundation Therapeutics	Phase 2	2004-09-01	Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main causes of death in individuals with CF. The purpose of this study is to compare the effectiveness of treatment based on quarterly culture results versus consistent quarterly antibiotic treatment at reducing PA infection in children with CF.

Clinical Trial Conditions for Tobramycin

Condition Name

Condition Name for Tobramycin
Intervention	Trials
Cystic Fibrosis	48
Cataract	5
Pseudomonas Aeruginosa	4
Fractures, Open	3

Condition MeSH

Condition MeSH for Tobramycin
Intervention	Trials
Cystic Fibrosis	55
Fibrosis	50
Pseudomonas Infections	17
Infections	11

Clinical Trial Locations for Tobramycin

Trials by Country

Trials by Country for Tobramycin
Location	Trials
United States	490
Italy	55
Spain	20
France	19
United Kingdom	19

Trials by US State

Trials by US State for Tobramycin
Location	Trials
Texas	22
Ohio	22
Pennsylvania	22
New York	22
Florida	21

Clinical Trial Progress for Tobramycin

Clinical Trial Phase

Clinical Trial Phase for Tobramycin
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	33
Phase 3	37

Clinical Trial Status

Clinical Trial Status for Tobramycin
Clinical Trial Phase	Trials
Completed	77
Unknown status	15
Terminated	10

Clinical Trial Sponsors for Tobramycin

Sponsor Name

Sponsor Name for Tobramycin
Sponsor	Trials
Novartis Pharmaceuticals	15
Cystic Fibrosis Foundation	8
Cystic Fibrosis Foundation Therapeutics	7

Sponsor Type

Sponsor Type for Tobramycin
Sponsor	Trials
Other	150
Industry	77
NIH	5

TOBRAMYCIN: Clinical Trials Update and Market Outlook

Last updated: April 25, 2026

What is the clinical development and approval footprint for tobramycin?

Tobramycin is an established aminoglycoside antibiotic with multiple approved formulations across respiratory infection indications, most notably chronic Pseudomonas aeruginosa infection in cystic fibrosis (CF). The global clinical trial footprint is largely shaped by (1) inhaled tobramycin regimens designed to improve lung exposure while limiting systemic toxicity, and (2) direct comparisons against other inhaled antibiotics used in CF respiratory disease.

Key market-relevant clinical pattern: inhaled tobramycin products are typically trialed in randomized, placebo-controlled designs that measure sputum Pseudomonas density, time to exacerbation, exacerbation frequency, and patient-centered endpoints such as pulmonary function in CF cohorts. In non-CF settings, trials have been less frequent and more formulation- and protocol-dependent.

Approved, market-shaping formulations (commercial baseline)

• Inhaled tobramycin solution (TIS): marketed as tobramycin inhalation solution, commonly delivered in cyclic regimens.
• Inhaled tobramycin powder in dry powder inhaler (TPI): marketed as a dry powder formulation for CF bronchopulmonary infection management.
• Tobramycin ophthalmic products: conventional and extended-dosing ophthalmic formulations exist for bacterial keratitis/conjunctival infections, with separate competitive dynamics from inhaled CF products.
• Topical/nebulized tobramycin in other indications: typically smaller markets and more country-specific availability.

Because tobramycin is off-patent in many regions, most incremental clinical activity and market capture occurs via formulation life-cycle management (dose delivery, inhalation device performance, tolerability, adherence) rather than new molecular entity (NME) development.

What clinical trials are driving the most actionable updates?

A complete, live clinical trials register snapshot depends on ongoing database pulls and near-real-time registry changes. No such registry inputs are provided in the prompt, so a definitive list of current active trials, recruitment statuses, and primary completion dates cannot be produced without risking incorrect omissions or mischaracterization.

How is tobramycin positioned in current respiratory antibiotic competition?

Tobramycin’s competitive set in CF respiratory infection typically includes:

• Other inhaled antibiotics (including polymyxins, fluoroquinolones, and beta-lactams in selected contexts)
• Newer inhaled agents and reformulated inhaled antibiotics with different dosing schedules and device attributes
• Adjunct respiratory infection management strategies that influence antibiotic rotation and cycling choices

The market power of inhaled tobramycin historically comes from:

• Deep guideline embedding in CF chronic Pseudomonas management pathways
• Long-term clinical familiarity in practice
• Predictable dosing regimens and physician comfort

Market pressure is mainly on adherence and switching. Dry powder and device-linked convenience can shift share, especially where payers and specialty centers standardize formulary selections.

What do guidelines imply for near-term use?

Clinical practice guidelines for CF chronic Pseudomonas typically recommend inhaled antibiotics, including tobramycin-based options, with cyclic use or regimen rotation strategies. Guideline-directed continuity tends to sustain baseline volume for established agents even as newer drugs enter.

A key practical driver is that CF care centers often use a set of preferred inhaled antibiotics and rotate based on patient response, exacerbation patterns, and tolerability.

How does tobramycin fit the economics of CF chronic Pseudomonas care?

Even where tobramycin faces generic pressure, the commercial model for inhaled antibiotics often has three pricing and volume levers:

1. Formulation choice: liquid nebulized regimens versus dry powder regimens
2. Device adherence: time-to-dose and patient preference shift share within the same active ingredient class in some settings
3. Formulary allocation: payers may concentrate use into fewer agents or those with preferred reimbursement terms

Because inhaled tobramycin has multiple competitors and multiple formulations, the share outcome often depends more on contracting and center formulary than on molecule innovation.

---

Market Analysis: Demand Drivers, Supply Dynamics, and Share Drivers

What drives demand for inhaled tobramycin?

Demand is anchored to prevalence and treatment intensity in CF:

• CF patient pool treated at specialized centers
• Chronic Pseudomonas management intensity, including cyclical antibiotic use
• Exacerbation rates and the clinical decision to escalate inhaled antibiotic therapy during instability

Growth can come from:

• Expanded CF newborn screening and improved survival (bigger patient pool)
• Higher treatment intensity per patient in certain geographies (center practice variation)
• Device and adherence improvements (switching from nebulized to dry powder regimens in some markets)

What constrains growth?

• Generic entry and price erosion in many markets
• Antibiotic stewardship and resistance considerations that can reduce long-term use in select subgroups
• Switching to other inhaled antibiotics based on tolerability or perceived efficacy
• Healthcare budget constraints in payers

Supply and competitive landscape

Tobramycin is widely available, and supply is shaped by:

• Multiple manufacturers for generic inhaled products in many jurisdictions
• Device and formulation-specific supply constraints (particularly where proprietary inhaler systems apply)

The competitive fight is less about “can it be made” and more about “who wins reimbursement and formulary preference.”

---

Market Projection: 5-Year View and Scenario Logic

How should tobramycin be projected given generic pressure and formulation differentiation?

A projection for tobramycin depends on splitting the market into at least two commercial buckets:

1. Inhaled tobramycin (liquid nebulized): subject to stronger generic price competition, cyclic regimens, and contracting-led share shifts
2. Inhaled tobramycin (dry powder): subject to adherence-led switching, with slower price erosion if device ecosystem and payer preference reduce substitutability

A defensible projection approach uses:

• CF treated prevalence trend
• Average number of inhaled antibiotic treatment cycles per year per patient
• Price trend reflecting generic erosion offset by regimen substitution
• Share drift driven by device convenience and formulary tightening

Base-case market growth framework (directional)

Given the established role and the generic pressure profile, the likely near-term outcome is:

• Volume stability or modest growth driven by CF population dynamics
• Revenue growth lagging volume due to price erosion
• Potential share gains where dry powder regimens improve adherence and facility preference

A precise numeric forecast requires market size baselines by geography and formulation, which are not provided in the prompt. Producing hard numbers without those inputs would risk accuracy and mislead decision-making.

---

Commercial Implications for R&D and Investment

Where does incremental value still exist for tobramycin-based assets?

For off-patent molecules, incremental value is concentrated in:

• Device-linked differentiation (dose delivery consistency, reduced handling time, improved inhalation technique usability)
• Protocol optimization (cycle length, dosing frequency, combination schedules that reduce exacerbations)
• Patient segmentation (subgroups with intolerance or inadequate response where regimen choice matters)

What is the highest-probability win theme versus competitors?

• Adherence and usability: dosing experience that reduces missed treatments
• Formulary fit: payer contracting that positions a formulation as the default inhaled tobramycin option
• Clinical endpoints tied to payer outcomes: reduced exacerbations and lower acute-care utilization versus comparator inhaled antibiotics

---

Key Takeaways

• Tobramycin’s commercial center of gravity is inhaled therapy for chronic Pseudomonas management in CF, anchored by guideline-consistent cyclic use.
• Near-term clinical activity and market movement tend to be formulation and regimen driven rather than NME-driven.
• Market outlook is constrained by generic price erosion but supported by CF population growth and practice-level switching between nebulized and dry powder options.
• The actionable commercial battleground is device adherence, formulary contracting, and regimen optimization tied to exacerbation outcomes.

---

FAQs

1. Is tobramycin still being used in cystic fibrosis chronic Pseudomonas infection?
   Yes. Inhaled tobramycin remains a core option in CF chronic Pseudomonas management with cyclic regimens.

2. What formulation differences matter most commercially?
   Nebulized liquid regimens versus dry powder inhaler delivery, where device convenience and adherence can shift share.

3. Does patent status drive tobramycin’s market pricing?
   Yes. Widespread generic availability compresses pricing, making revenue growth more sensitive to volume and share within formulation types.

4. What endpoints matter in tobramycin clinical studies?
   Sputum Pseudomonas density and exacerbation-related endpoints, often alongside pulmonary function and tolerability.

5. What is the most likely driver of near-term market share movement?
   Formulary placement and device-linked adherence differences between inhaled tobramycin formulations and comparator inhaled antibiotics.

---

References

[1] Cystic Fibrosis Foundation. Clinical Care Guidelines for Cystic Fibrosis. (Latest guideline versions accessible via CF Foundation).
[2] European Medicines Agency (EMA). Product information and assessment documents for tobramycin-containing medicinal products.
[3] U.S. Food and Drug Administration (FDA). Labeling and approval history for inhaled tobramycin products and related ophthalmic formulations.